Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial

Author(s):
Lam, S.W.; Groot, S.M. de; Honkoop, A.H.; Jager, A.; Tije, A.J. ten; Bos, M.M.E.M.; Linn, S.C.; Bosch, J. van den; Kroep, J.R.; Braun, J.J.; Tinteren, H. van; ; Dutch Breast Canc Res Grp BOOG
Published
2014
Publication type
Article / Letter to editor
Metastatic breast cancerPhase 2 trialPaclitaxelCapecitabineBevacizumab
Date issued
2014-12-31
Language
English
Is part of
European Journal of Cancer (2014), Vol. 50, no. 18, p. 3077-3088
hdl
1887/104659
doi
10.1016/j.ejca.2014.10.008